Pharmacogenetic issues in thorough QT trials

被引：7
作者：
Judson, Richard S.
Salisbury, Benjamin A.
Reed, Carol R.
Ackerman, Michael J.
机构：
[1] SpyroPharma, Guilford, CT USA
[2] Clin Data Inc, New Haven, CT USA
[3] Mayo Clin, Coll Med, Sudden Death Genom Lab, Rochester, MN USA
来源：
MOLECULAR DIAGNOSIS & THERAPY | 2006年 / 10卷 / 03期
关键词：
D O I：
10.1007/BF03256454
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Drug-induced QT prolongation (DI-LQT), through its associated arrhythmias, is a leading cause of drugs being withdrawn from the market. As a consequence, the US FDA and other regulatory agencies are mandating that all new drugs go through a so-called 'Thorough QT' (TQT) study to evaluate the potential for 'QT liability', specifically the potential for a drug to cause a discernible increase in the QT interval. Several genetic factors that modulate the risk of DI-LQT have been discovered. These are genes responsible for the congenital long QT syndrome, drug metabolism genes (mainly CYP2D6 and CYP3A4), and genes in other regulatory pathways. Here, we briefly review the links between genetic variants and drug-induced QT risk, and propose approaches to consider for using pharmacogenetics in planning and analyzing TQT studies.
引用
收藏
页码：153 / 162
页数：10
相关论文
共 76 条
[1]   MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia [J].
Abbott, GW ;
Sesti, F ;
Splawski, I ;
Buck, ME ;
Lehmann, WH ;
Timothy, KW ;
Keating, MT ;
Goldstein, SAN .
CELL, 1999, 97 (02) :175-187
[2]   Stilbenes and fenamates rescue the loss of IKS channel function induced by an LQT5 mutation and other IsK mutants [J].
Abitbol, I ;
Peretz, A ;
Lerche, C ;
Busch, AE ;
Attali, B .
EMBO JOURNAL, 1999, 18 (15) :4137-4148
[3]   Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: Implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing [J].
Ackerman, MJ ;
Splawski, I ;
Makielski, JC ;
Tester, DJ ;
Will, ML ;
Timothy, KW ;
Keating, MT ;
Jones, G ;
Chadha, M ;
Burrow, CR ;
Stephens, JC ;
Xu, CB ;
Judson, R ;
Curran, ME .
HEART RHYTHM, 2004, 1 (05) :600-607
[4]   Cardiac channelopathies: it's in the genes [J].
Ackerman, MJ .
NATURE MEDICINE, 2004, 10 (05) :463-464
[5]   Ethnic differences in cardiac potassium channel variants: Implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome [J].
Ackerman, MJ ;
Tester, DJ ;
Jones, GS ;
Will, ML ;
Burrow, CR ;
Curran, ME .
MAYO CLINIC PROCEEDINGS, 2003, 78 (12) :1479-1487
[6]   Unique topographical distribution of m cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome [J].
Akar, FG ;
Yan, GX ;
Antzelevitch, C ;
Rosenbaum, DS .
CIRCULATION, 2002, 105 (10) :1247-1253
[7]   Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism [J].
Anderson, CL ;
Delisle, BP ;
Anson, BD ;
Kilby, JA ;
Will, ML ;
Tester, DJ ;
Gong, QM ;
Zhou, ZF ;
Ackerman, MJ ;
January, CT .
CIRCULATION, 2006, 113 (03) :365-373
[8]  
Anson BD, 2005, LANCET, V365, P682, DOI 10.1016/S0140-6736(05)70936-3
[9]   The QT interval [J].
Bednar, MM ;
Harrigan, EP ;
Anziano, RJ ;
Camm, AJ ;
Ruskin, JN .
PROGRESS IN CARDIOVASCULAR DISEASES, 2001, 43 (05) :1-45
[10]   A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization [J].
Bezzina, CR ;
Verkerk, AO ;
Busjahn, A ;
Jeron, A ;
Erdmann, J ;
Koopmann, TT ;
Bhuiyan, ZA ;
Wilders, R ;
Mannens, MMAM ;
Tan, HL ;
Luft, FC ;
Schunkert, H ;
Wilde, AAM .
CARDIOVASCULAR RESEARCH, 2003, 59 (01) :27-36
12345678